Double-stranded RNA to mimic viral infection for cancer immunotherapy

The presence of moieties denoting viral infection is crucial to mount powerful cytotoxic T-cell immune responses acting through innate receptors such as Toll-like receptor 3 (TLR3). For cancer immunotherapy, several safe analogues of viral double-stranded RNA (dsRNA) are under clinical development following compelling evidence for efficacy in mouse models.